Abbott, which has a 10 percent stake in Evalve, will pay as much as $410 million for its acquisition in a deal that will give Abbott a presence in the field of non-surgical treatments for heart disease according to John Capek, the company"s executive vice president for medical devices. Evalve is currently testing the MitraClip system which is used to treat mitral regurgitation without the need for open heart surgery. The system is already approved in Europe and it is expected to be approved by 2011 in the US.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지